Purevax® range now available in 0.5 ml presentation

Ingelheim, Germany, October 22, 2020 – Boehringer Ingelheim, a market leader in animal health, announces the upcoming release of its Purevax^® vaccine range for cats in 0.5 ml presentation. Thanks to its small volume, this new presentation of Purevax^® makes cat vaccination convenient, allowing for a more gentle immunization experience for feline patients.

The Purevax^® range protects cats from contracting the most important infectious feline diseases: feline herpesvirus (FHV) and feline calicivirus (FCV), feline panleukopenia virus (FPV), chlamydia felis, feline leukemia virus (FeLV) as well as rabies. Purevax^® is the only fully adjuvant‑free feline vaccine range, combining optimal safety with proven efficacy. The Purevax^® range also allows for flexibility by using the core components alone or in combination with non-core components, depending on the individual need of the cat.

“Purevax^® 0.5 ml offers the same broad and flexible product range* as Purevax^® 1.0 ml, with tailor-made solutions to suit every cat’s lifestyle. The new cat-friendly injection volume of 0.5 ml is a key benefit we are very excited about,” comments Dr Sandrine Lachérade, Global Marketing Director Pet Vaccines at Boehringer Ingelheim,” adding: “Veterinarians can count on Purevax^® 0.5 ml to have the same efficacy as the Purevax^® 1.0 ml range.”

Dr Jean-Philippe Tronel, Global Technical Director Pet Vaccines at Boehringer Ingelheim, gives further details: “Safety studies¹ comparing the two presentations were carried out to obtain the EMA variation. The results of these studies, and especially the large-scale field trial in veterinary practices, suggested an improvement versus the already uncompromised safety of the 1.0 ml presentation¹.”

The 0.5 ml vaccines contain the same amount and quality of antigens as the 1.0 ml products, so we have the same level of efficacy,” he elaborates. “Reducing the volume significantly provides an easier faster and smoother vaccination process.”

PUREVAX^® also provides:

• Synergistic and broader protection with the most recent** and dual inactivated FCV vaccine strains^2-4
• Rapid protection with one-week onset of immunity for core RCP components⁵
• Sustained protection up to three years for RCP and rabies components^6-8
• Powerful immune response without adjuvant, thanks to innovative canarypox FeLV/rabies technology^9-12

Boehringer Ingelheim expects to bring Purevax^® 0.5 ml range to several markets worldwide in 2021.

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

References

* PUREVAX Rabies remains in 1mL

** As of 2020

¹Data on file

²Poulet H, et al. Vaccine 2008;26:3647‑54

³Addie D, et al. Vet Rec 2008;163:355‑7

⁴Poulet H, et al. Vet Microbiol 2005;106:17‑31

⁵Jas D, et al. Vet J 2009;182:86‑93

⁶PUREVAX® registration file

⁷Jas D, et al. Vet Microbiol 2015;177:123‑31

⁸Jas D, et al. Vaccine 2012;30:6991‑6

⁹Jas D, et al. Vaccine 2012;30:6991‑6

¹⁰Hofmann‑Lehmann R, et al. Vaccine 2006;24:1087‑94

¹¹El Garch H, et al. Intern J Appl Res Vet Med 2006;4:100‑8

¹²Poulet H, et al. Vaccine 2007;25:5606‑12